VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key opinion leaders (KOLs) focused on major depressive disorder.
Webinar : | “XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs” |
Date : | Tuesday, September 19, 2023 |
Time : | 11:30 am – 1 pm ET Eastern Time (8:30 am – 11 am Pacific Time) |
Link : | Participants can register and access the webinar on the Investors section of Xenon’s website. |
Format : | Questions may be submitted (via chat function) during the live webinar or submitted in advance via email . |
Speakers include:
- Sanjay J. Mathew, MD, Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research Professor of Psychiatry & Behavioral Sciences Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine
- James W. Murrough, MD, PhD, Professor of Psychiatry and Neuroscience Director, Depression and Anxiety Center for Discovery and Treatment Icahn School of Medicine at Mount Sinai
- Ian Mortimer, President and CEO, Xenon Pharmaceuticals (moderator)
- Chris Kenney, Chief Medical Officer, Xenon Pharmaceuticals
- Chris Von Seggern, Chief Commercial Officer, Xenon Pharmaceuticals
A live webcast of the company presentation will be available on the “ Investors ” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact :
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com